Drugs / Trifluridine/Tipiracil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04894123 | Feb 2022 → Feb 2023 | colorectal adenocarcinoma, gastroesophageal cancer | GERCOR - Multidisciplinary Oncology Cooperative Group | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trifluridine/Tipiracil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04894123 ↗ |
| Route | Oral | “35 mg/m² orally twice a day from day 1 to day 5 every 14 days” NCT04894123 ↗ |